Arcus Biosciences (RCUS) Operating Leases (2020 - 2022)

Arcus Biosciences' Operating Leases history runs 3 years deep, the most recent figure standing at $119.2 million for Q3 2022.

• On a quarterly basis, Operating Leases rose 130.55% year-over-year to $119.2 million in Q3 2022; TTM through Sep 2022 was $119.2 million, a 130.55% increase from a year earlier, with the FY2021 full-year figure at $116.9 million, up 666.82% from the prior year.
• Operating Leases retreated to $119.2 million in Q3 2022 per RCUS's latest filing, from $121.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $121.3 million in Q2 2022 and bottomed at $14.7 million in Q1 2021.
• The 3-year median for Operating Leases is $83.5 million (2021), against an average of $75.8 million.
• Biggest YoY gain for Operating Leases was 680.74% in 2022; the steepest drop was 130.55% in 2022.
• Year by year, Operating Leases stood at $15.2 million in 2020, then jumped by 666.82% to $116.9 million in 2021, then increased by 1.97% to $119.2 million in 2022.
• Per Business Quant, the three latest RCUS Operating Leases figures stand at $119.2 million (Q3 2022), $121.3 million (Q2 2022), and $114.8 million (Q1 2022).